Hanna Squire

Dr. Hanna Squire

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2023 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
KHKieran S Hand
Kieran S Hand
Diane Ashiru-OredopeDiane Ashiru-Oredope
Diane Ashiru-Oredope
EBElizabeth Beech
Elizabeth Beech
SBSabine Bou-Antoun
Sabine Bou-Antoun
GDGillian Damant
Gillian Damant
JFJeff Featherstone
Jeff Featherstone
NHS England designs and administers improvement and assurance schemes that include elements to incentivize prudent use of antimicrobials, optimise patient outcomes, minimise avoidable exposure to antimicrobials, and reduce selection pressure for antimicrobial resistance (AMR). These schemes include the NHS System Oversight Framework, the Pharmacy Quality Scheme for community pharmacies, the NHS Standard Contract, and the Commissioning for Quality and Innovation (CQUIN) framework. This report describes the schemes implemented from 2021 to 2022, and it reports the scheme performance of NHS commissioners and healthcare provider organisations. A summary of improvement and assurance schemes from 2022 to 2023 is also provided.

1 March 2023 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
ALAlessandra Lochen
Alessandra Lochen
HSHanna Squire
Hanna Squire
Diane Ashiru-OredopeDiane Ashiru-Oredope
Diane Ashiru-Oredope
KHKieran S Hand
Kieran S Hand
HHHassan Hartman
Hassan Hartman
HSHanna Squire
Hanna Squire
The UK Health Security Agency’s (UKHSA) COVID-19 therapeutics programme was commissioned by the Department of Health and Social Care with the remit to evaluate the use and role of COVID-19 treatments. COVID-19 therapeutics data were assessed from two main data sources: novel therapy requests via Blueteq and medicines supply data via Rx-info. The five COVID-19 therapies in use in England between 1 October 2021 and 31 March 2022 included nirmatrelvir plus ritonavir, remdesivir, molnupiravir, sotrovimab, and casirivimab with imdevimab. During this time period, treatment requests for novel therapies against COVID-19 were submitted for nearly 52,000 patients in England. The UKHSAs COVID-19 therapeutics programme has been key to supporting the deployment of novel COVID-19 therapies in England by undertaking genomic, virological, and epidemiologic surveillance, through both national surveillance systems and academic collaboration. Effective therapies are particularly important for protecting the health of patients at greater risk of developing severe COVID-19. This national surveillance and stewardship programme was successfully rolled out at pace at the start of the pandemic and leads on work nationally to reduce the development of resistance. These findings were presented at the ESPAUR Report webinar on 23 November 2022.

15 May 2024 in COVID
Verified
Journal Article
Open access
PDF file
AFAngela Falola
Angela Falola
HSHanna Squire
Hanna Squire
SBSabine Bou-Antoun
Sabine Bou-Antoun
ALAlessandra Lochen
Alessandra Lochen
CBColin S. Brown
Colin S. Brown
ADAlicia Demirjian
Alicia Demirjian
Coronavirus disease-19 (COVID-19) has disproportionately affected certain demographics in England, exacerbating existing health disparities. Effective therapeutics are a critical line of defence against COVID-19, particularly for patients at elevated risk for severe disease. Surveillance systems were established to monitor the usage of COVID-19 therapeutics in hospital and community settings and to inform stewardship. Three antiviral therapies—nirmatrelvir plus ritonavir (Paxlovid®), remdesivir (Veklury®), and molnupiravir (Lagevrio®)—and two neutralising monoclonal antibody therapies (nMAbs)—sotrovimab (Xevudy®) and casirivimab with imdevimab (Ronapreve®)—were in use in England between July 2020 and April 2023. This paper aims to illuminate trends in the utilisation of COVID-19 therapeutics treatment in both hospital and community settings, stratified by the Index of Multiple Deprivation (IMD) in England. Chapter 3 of the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2022 to 2023 also discusses the epidemiological surveillance of these five directly acting antiviral COVID-19 therapeutics’ use in England between 2022 and 2023.

18 January 2023 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
SBSabine Bou-Antoun
Sabine Bou-Antoun
AFAngela Falola
Angela Falola
HFHolly Fountain
Holly Fountain
HSHanna Squire
Hanna Squire
CBColin S. Brown
Colin S. Brown
ADAlicia Demirjian
Alicia Demirjian
The UK’s 5-year National Action Plan for Antimicrobial Resistance has an ambition to reduce total antimicrobial consumption, a key driver of antimicrobial resistance, in humans by 15% by 2024, highlighting the need for active surveillance to inform on progression. The English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) report, Chapter 3, commentates on key national antimicrobial consumption trends, across primary and secondary care in England, between 2017 to 2021. These findings were presented at the ESPAUR Report webinar on 23 November 2022.

20 March 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
AFAngela Falola
Angela Falola
HSHanna Squire
Hanna Squire
SBSabine Bou-Antoun
Sabine Bou-Antoun
ALAlessandra Lochen
Alessandra Lochen
CBColin S. Brown
Colin S. Brown
ADAlicia Demirjian
Alicia Demirjian
Coronavirus disease-19 (COVID-19) has disproportionately affected certain demographics in England, exacerbating existing health disparities. Effective therapeutics are a critical line of defence against COVID-19, particularly for patients at elevated risk for severe disease. Surveillance systems were established to monitor usage of COVID-19 therapeutics in hospital and community settings and inform stewardship. Three antiviral therapies: nirmatrelvir plus ritonavir (Paxlovid®), remdesivir (Veklury®), and molnupiravir (Lagevrio®); and two neutralising monoclonal antibody therapies (nMAbs): sotrovimab (Xevudy®) and casirivimab with imdevimab (Ronapreve®); were in use in England between July 2020 to April 2023. This paper aims to illuminate trends in the utilisation of COVID-19 therapeutics treatment in both hospital and community settings, stratified by the Index of Multiple Deprivation (IMD) in England. Chapter 3 of the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) report 2022 to 2023 also discusses the epidemiological surveillance of these five directly-acting antiviral COVID-19 therapeutics use in England between 2022 to 2023.